Blood Biomarker Kallikrein-8 Detects Amnestic Mild Cognitive Impairment
|
By LabMedica International staff writers Posted on 10 Jan 2022 |
|
Image: The Human KLK8/Kallikrein-8 ELISA Kit PicoKine is used to quantitate Human KLK8 in cell culture supernatants, cell lysates, serum and plasma (heparin, EDTA) (Photo courtesy of Boster Biological Technology)
Alzheimer’s disease (AD) is a neurodegenerative disease and the most common cause of dementia. AD starts to damage the brain 20 years or more before any clinical symptoms appear. The currently available biomarker for AD (beta-amyloid (Aβ, A), tau (T), and neurodegeneration (N), (ATN)) are measured in cerebrospinal fluid (CSF).
The extracellular serine protease kallikrein-8 (KLK8, alias neuropsin) is a well-known, dose-dependent modulator of neuroplasticity and memory. It unfolds its effects in part by processing the substrates neuregulin-1, neuronal cell adhesion molecule L1, fibronectin, and ephrin receptor B2, and thereby regulates different neuroplasticity associated signaling pathways.
Neuropathologists at the University Hospital Essen (Essen, Germany) and their colleagues examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of AD, compared to cognitively unimpaired (CU) controls. Forty cases and 80 controls, matched by sex and age (± 3years), were participants of the longitudinal population-based Heinz Nixdorf Recall study. Standardized cognitive performance was assessed five (T1) and 10 years after baseline (T2).
KLK8 levels were measured in duplicate using a commercially obtained ELISA kit (Boster Biological Technology, Pleasanton, CA, USA). To discriminate between the APOE alleles ε2, ε3, and ε4, Cardio-MetaboChip BeadArrays were used for genotyping of two single-nucleotide polymorphisms (rs7412 and rs429358). Participants defined as APOE ε4 positive had at least one allele 4 (2/4, 3/4, 4/4). All other participants were defined as APOE ε4 negative.
The investigators reported that the 37 participants with aMCI had a higher KLK8 mean value compared to the 72 CU participants (911.6 ± 619.8 pg/mL versus 783.1 ± 633.0 pg/mL). Participants with aMCI were more often APOE ε4 positive compared to CU participants (48.6 versus 26.4%). Fully adjusted, a KLK8 increase of 500pg/mL was associated with a 2.68 (1.05–6.84) higher chance of having aMCI compared to being CU. With an AUC of 0.92 (0.86–0.97), blood KLK8 was a strong discriminator for aMCI and CU.
The authors concluded that the population-based case-control study demonstrated the capability of KLK8 as a blood biomarker for early diagnosis of AD. A 500 pg/mL increase in blood KLK8 was associated with an almost threefold increased chance of an aMCI diagnosis compared to cognitively unimpaired participants. The diagnostic performance of KLK8 in blood for aMCI was very good with an AUC of 0.92. The study was published on December 20, 2021 in the journal Alzheimer's Research & Therapy.
Related Links:
University Hospital Essen
Boster Biological Technology
The extracellular serine protease kallikrein-8 (KLK8, alias neuropsin) is a well-known, dose-dependent modulator of neuroplasticity and memory. It unfolds its effects in part by processing the substrates neuregulin-1, neuronal cell adhesion molecule L1, fibronectin, and ephrin receptor B2, and thereby regulates different neuroplasticity associated signaling pathways.
Neuropathologists at the University Hospital Essen (Essen, Germany) and their colleagues examined whether blood KLK8 is elevated in persons with amnestic mild cognitive impairment (aMCI) which is a precursor of AD, compared to cognitively unimpaired (CU) controls. Forty cases and 80 controls, matched by sex and age (± 3years), were participants of the longitudinal population-based Heinz Nixdorf Recall study. Standardized cognitive performance was assessed five (T1) and 10 years after baseline (T2).
KLK8 levels were measured in duplicate using a commercially obtained ELISA kit (Boster Biological Technology, Pleasanton, CA, USA). To discriminate between the APOE alleles ε2, ε3, and ε4, Cardio-MetaboChip BeadArrays were used for genotyping of two single-nucleotide polymorphisms (rs7412 and rs429358). Participants defined as APOE ε4 positive had at least one allele 4 (2/4, 3/4, 4/4). All other participants were defined as APOE ε4 negative.
The investigators reported that the 37 participants with aMCI had a higher KLK8 mean value compared to the 72 CU participants (911.6 ± 619.8 pg/mL versus 783.1 ± 633.0 pg/mL). Participants with aMCI were more often APOE ε4 positive compared to CU participants (48.6 versus 26.4%). Fully adjusted, a KLK8 increase of 500pg/mL was associated with a 2.68 (1.05–6.84) higher chance of having aMCI compared to being CU. With an AUC of 0.92 (0.86–0.97), blood KLK8 was a strong discriminator for aMCI and CU.
The authors concluded that the population-based case-control study demonstrated the capability of KLK8 as a blood biomarker for early diagnosis of AD. A 500 pg/mL increase in blood KLK8 was associated with an almost threefold increased chance of an aMCI diagnosis compared to cognitively unimpaired participants. The diagnostic performance of KLK8 in blood for aMCI was very good with an AUC of 0.92. The study was published on December 20, 2021 in the journal Alzheimer's Research & Therapy.
Related Links:
University Hospital Essen
Boster Biological Technology
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Piezoelectric Micropump
Disc Pump
New
Lyme Disease Test
Lyme IgG/IgM Rapid Test Cassette
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read more
Hematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read more
Immunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read more
Microbiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Pathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read more
Technology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read more
Industry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more
